MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s potential ...
Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Subjects will be randomly allocated 1:1 to receive Tyvaso or placebo. All subjects will initiate Tyvaso or ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
Hosted on MSN
MannKind upgraded by RBC, Tyvaso DPI royalties cited
RBC has upgraded MannKind (NASDAQ:MNKD) to outperform from sector perform, citing the company’s Tyvaso DPI royalty revenue opportunity and orphan lung pipeline. The investment bank estimates the ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...
The tentative approval cannot take effect because a competing product was granted market exclusivity. A new formulation of treprostinil (Yutrepia) could soon be available to patients with pulmonary ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results